Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
David W. Cragg, insider at Cytokinetics
David W. Cragg Insider Alerts

Get notified the next time David W. Cragg buys or sells Cytokinetics stock. Enter your email address below to get our daily insider buying and selling report.

David W. Cragg Insider Information

Insider of Cytokinetics

Dave has led our Human Resources department since he joined us in February 2005. Dave was promoted to SVP in 2009 and to Chief Human Resources and Administration Officer in March 2019.

Prior to joining Cytokinetics, Dave managed his own human resources consulting practice, assisting organizations with building human resources infrastructure. During his extensive HR career, Dave held HR leadership roles with a number of biotechnology and high technology companies, including eGroups Inc. (acquired by Yahoo! Inc.), Genentech, Inc., Software Publishing Corporation, West Marine, Inc., and LSI Logic Corporation.

Mr. Cragg holds a B.A. in Industrial Psychology from the University of California, Santa Cruz.

Dave keeps busy in his personal time as an avid car enthusiast with several classic cars, vintage hifi equipment and canoeing. He also serves on the ALSA Golden West Chapter Board of Directors.

What is David W. Cragg's salary?

As the Insider of Cytokinetics, Incorporated, Mr. Cragg earned a total compensation package of $1,837,117.00 in 2020. Mr. Cragg earned a salary of $396,391.00, stock awards of $432,000.00, options awards of $864,000.00, non-equity compensation of $135,412.00, and other compensation of $9,314.00.

How do I contact David W. Cragg?

The corporate mailing address for Mr. Cragg and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]

Has David W. Cragg been buying or selling shares of Cytokinetics?

Within the last three months, David W. Cragg has sold $3,017,425.00 of Cytokinetics stock. Most recently, David Cragg sold 45,000 shares of the business's stock in a transaction on Tuesday, November 9th. The shares were sold at an average price of $41.76, for a transaction totalling $1,879,200.00.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Robert Blum (CEO), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), and Sandford Smith (Director).

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 53 times. They sold a total of 884,569 shares worth more than $21,758,253.93. The most recent insider tranaction occured on November, 19th when Director Sandford D Smith sold 29,032 shares worth more than $1,196,408.72. Insiders at Cytokinetics own 5.7 % of the company.

Information on this page was last updated on 11/19/2021.

David W. Cragg Insider Trading History at Cytokinetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2021Sell45,000$41.76$1,879,200.00View SEC Filing Icon  
11/1/2021Sell25,000$34.89$872,250.00View SEC Filing Icon  
10/1/2021Sell7,569$35.14$265,974.66View SEC Filing Icon  
8/2/2021Sell2,616$29.67$77,616.72View SEC Filing Icon  
6/1/2021Sell14,999$21.63$324,428.37View SEC Filing Icon  
See Full Table

David W. Cragg Buying and Selling Activity at Cytokinetics

This chart shows David Cragg's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $35.50
Low: $35.01
High: $38.50

50 Day Range

MA: $37.64
Low: $33.59
High: $41.73

2 Week Range

Now: $35.50
Low: $16.05
High: $42.87

Volume

1,480,484 shs

Average Volume

864,698 shs

Market Capitalization

$2.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!